Slow titration (increasing dose every 4 weeks) significantly reduces the severity and frequency of these effects compared to starting at higher doses immediately
Beyond gastrointestinal effects, clinical data and class-level evidence from licensed incretin agents (semaglutide, tirzepatide) have flagged concerns regarding: Heart rate elevation: Increases in resting heart rate are a recognised class effect of GLP-1 receptor agonists, documented in the SmPCs for semaglutide (Wegovy) and tirzepatide (Mounjaro)
Employees using these medications may benefit from nutrition guidance and working with a Registered Dietitian, adequate protein intake, and strength training support (Reference)
For patients with type 2 diabetes, alternative glucose-lowering medications such as SGLT2 inhibitors or metformin provide metabolic benefits, though with less pronounced weight effects
Available strengths include 10mg, 12mg, 15mg, 20mg, 24mg, 30mg, and 40mg, providing flexibility for both small-scale and long-term research projects